CD22 and B-cell chronic lymphocytic leukemia: The activity of bryostatin 1 is attributed to its interaction with the diacylglycerol biding site of the C-1 regulatory domain of protein kinase C. Upregulation of CD22 was noted alongside an increase in cell size and membrane projections in bryostatin-treated CLL (chronic lymphocytic leukemia) cells.